 "Cadila Healthcare hits record high on USFDA nod for Clonidine Hcl injection")
Cadila Healthcare is trading higher by 2% at Rs 1,019, extending its yesterday’s nearly 5% rally on the BSE, after the company said it has received the final approval from the US FDA to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.
Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices, indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone, reports suggest.
"The company now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04," Cadila Healthcare said in a statement.
The stock opened at Rs 1,005 and touched a record high of Rs 1,020 on the NSE. A combined 66,600 shares changed hands on the counter so far on the NSE and BSE.
Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices, indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone, reports suggest.
"The company now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04," Cadila Healthcare said in a statement.
The stock opened at Rs 1,005 and touched a record high of Rs 1,020 on the NSE. A combined 66,600 shares changed hands on the counter so far on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%